Triarylmethanes, a new class of Cx50 inhibitors

The paucity of specific pharmacological agents has been a major impediment for delineating the roles of gap junction channels formed by connexin proteins in physiology and pathophysiology. Here, we used the selective optimization of side activities (SOSA) approach, which has led to the design of hig...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: SILKE eBODENDIEK (Author), CLIO eRUBINOS (Author), MARIA PILAR TRELLES (Author), DAVID eJENKINS (Author), NICHOLE eCOLEMAN (Author), Heike eWulff (Author), MIDUTURU eSRINIVAS (Author)
Formato: Libro
Publicado: Frontiers Media S.A., 2012-06-01T00:00:00Z.
Subjects:
Acceso en liña:Connect to this object online.
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8266b94088a3497aa39900a60d6890ca
042 |a dc 
100 1 0 |a SILKE eBODENDIEK  |e author 
700 1 0 |a CLIO eRUBINOS  |e author 
700 1 0 |a MARIA PILAR TRELLES  |e author 
700 1 0 |a DAVID eJENKINS  |e author 
700 1 0 |a NICHOLE eCOLEMAN  |e author 
700 1 0 |a Heike eWulff  |e author 
700 1 0 |a MIDUTURU eSRINIVAS  |e author 
245 0 0 |a Triarylmethanes, a new class of Cx50 inhibitors 
260 |b Frontiers Media S.A.,   |c 2012-06-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2012.00106 
520 |a The paucity of specific pharmacological agents has been a major impediment for delineating the roles of gap junction channels formed by connexin proteins in physiology and pathophysiology. Here, we used the selective optimization of side activities (SOSA) approach, which has led to the design of high affinity inhibitors of other ion channels, to identify a specific inhibitor for channels formed by Cx50, a connexin subtype that is expressed in the lens. We initially screened a library of common ion channel modulating pharmacophores for their inhibitory effects on Cx50 gap junction channels, and identified four new classes of compounds. The triarlymethane (TRAM) clotrimazole was the most potent Cx50 inhibitor and we therefore used it as a template to explore the structure activity relationship (SAR) of the TRAMs for Cx50 inhibition. We here describe the design of T122 (N-[(2-methoxyphenyl)diphenylmethyl]-1,3-thiazol-2-amine) and T136 (N-[(2-iodophenyl)diphenylmethyl]-1,3-thiazol-2-amine), which inhibit Cx50 with IC50s of 1.2 µM and 2.4 µM. Both exhibit at least 10-fold selectivity over other connexins as well as major neuronal and cardiac voltage-gated K+ and Na+ channels. The SAR studies also indicated that the TRAM pharmacophore required for connexin inhibition is significantly different from the pharmacophore required for blocking the calcium-activated KCa3.1 channel. Both T122 and T136 selectively inhibited Cx50 gap junction channels in lens epithelial cells, suggesting that they could be used to further explore the role of Cx50 in the lens. In addition, our results indicate that a similar approach may be used to find specific inhibitors of other connexin subtypes. 
546 |a EN 
690 |a Gap Junctions 
690 |a ion channel 
690 |a triarylmethane 
690 |a inhibitors 
690 |a Structure-activity-relationship 
690 |a lens epithelial cells 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 3 (2012) 
787 0 |n http://journal.frontiersin.org/Journal/10.3389/fphar.2012.00106/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/8266b94088a3497aa39900a60d6890ca  |z Connect to this object online.